Prospective Validation of a Points Score System Predicting 30-day Survival
Launched by INDIANA UNIVERSITY · Oct 18, 2021
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to test a new tool that helps predict how long patients with metastatic cancer might survive after they start palliative radiation therapy. Palliative therapy is aimed at relieving symptoms and improving quality of life rather than curing the cancer. The study will gather important information about each patient, like their lab results and medical history, to give them a survival score when they join the trial.
To be eligible for this study, participants need to be at least 18 years old and have a diagnosis of cancer that has spread. They should be referred to radiation oncology for palliative treatments, but it’s important to note that patients can still participate even if they decide not to receive radiation or if it's not recommended for them. Those who start but don't finish their radiation treatment can also take part. Throughout the trial, participants can expect follow-up visits, which can be done virtually or over the phone.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥ 18 at time of consent
- • 2. Ability to provide written informed consent
- • 3. Cancer diagnosis referred to Radiation Oncology for palliative radiation therapy
- • 4. Patients who either choose to not receive radiation therapy or not recommended to receive radiation therapy will remain eligible
- • 5. Those patients who undergo a course of palliative radiation therapy, it is not the requirement of this study to complete that course of treatment. Those who prematurely end their course of treatment will remain eligible Note: Patients who ultimately either choose to not receive radiation or not recommended to receive radiation will remain eligible
- • Note: Patients who ultimately do not complete prescribed radiation will remain eligible
- Exclusion Criteria:
- • 1. Patients who are unable to participate in follow up visits per investigator discretion (virtual/phone follow up is permitted)
- • 2. Patients who are receiving definitive/curative course of radiation therapy
- • 3. Patients who self-report as pregnant or nursing
About Indiana University
Indiana University, a leading research institution, is committed to advancing healthcare through innovative clinical trials and rigorous scientific inquiry. With a focus on improving patient outcomes, the university conducts a wide range of studies across various medical disciplines, leveraging its extensive resources and collaborative networks. Indiana University's dedication to ethical research practices and community engagement ensures that its clinical trials not only contribute to scientific knowledge but also prioritize participant safety and well-being. Through its commitment to excellence, Indiana University plays a pivotal role in shaping the future of medicine and enhancing public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Indianapolis, Indiana, United States
Indianapolis, Indiana, United States
Indianapolis, Indiana, United States
Carmel, Indiana, United States
Avon, Indiana, United States
Carmel, Indiana, United States
Patients applied
Trial Officials
Naoyuki Saito, MD PhD
Principal Investigator
Indiana University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials